Oral cholesteryl ester transfer protein (CETP) inhibitors: a potential new approach for treating coronary artery disease.
Sikorski
James A
JA
Discovery Medicinal Chemistry, AtheroGenics, Inc., 8995 Westside Parkway, Alpharetta, Georgia 30004. jsikorski@atherogenics.com
D000284:Administration, Oral; D000818:Animals; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D053480:Cholesterol Ester Transfer Proteins; D003324:Coronary Artery Disease / Q000517:prevention & control* / Q000628:therapy; D006023:Glycoproteins / Q000037:antagonists & inhibitors*; D006801:Humans; D015394:Molecular Structure; D011412:Propanolamines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D013438:Sulfhydryl Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D013764:Tetrahydronaphthalenes / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D011412:Propanolamines; D011804:Quinolines; D013438:Sulfhydryl Compounds; D013764:Tetrahydronaphthalenes